A Trial of HRS4800 Tables in Healthy Male Subjects

NCT ID: NCT04573036

Last Updated: 2022-03-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-12
• Study Completion Date: 2021-09-20

Brief Summary

This is a single-site study to evaluate the safety, tolerability and pharmacokinetics (PK) of single dose administration of HRS4800, and the effect of food on the PK of HRS4800 in healthy male subjects.

Conditions

Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

HRS4800 tablets cohort 1

Part 1 - HRS4800 Single Ascending Dose

Group Type: EXPERIMENTAL

HRS4800 tablets

Intervention Type: DRUG

single oral administration

HRS4800 tablets cohort 2

Part 1 - HRS4800 Single Ascending Dose

Group Type: EXPERIMENTAL

HRS4800 tablets

Intervention Type: DRUG

single oral administration

HRS4800 tablets cohort 3

Part 1 - HRS4800 Single Ascending Dose

Group Type: EXPERIMENTAL

HRS4800 tablets

Intervention Type: DRUG

single oral administration

HRS4800 tablets cohort 4

Part 1 - HRS4800 Single Ascending Dose

Group Type: EXPERIMENTAL

HRS4800 tablets

Intervention Type: DRUG

single oral administration

HRS4800 tablets cohort 5

Part 2 - HRS4800 Food Effect

Group Type: EXPERIMENTAL

HRS4800 tablets

Intervention Type: DRUG

single oral administration

Placebo tablets

Group Type: PLACEBO_COMPARATOR

Placebo tablets

Intervention Type: DRUG

single oral administration

Interventions

HRS4800 tablets

single oral administration

Intervention Type: DRUG

Placebo tablets

single oral administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Able to understand the purposes and risks of the trial and comply with all study procedures before entering the trial, and provide signed informed consent.
• Male aged between 18 years and 55 years at screening, inclusive.
• Total body weight ≥50 kg at screening, and body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive.
• Agree to practice true abstinence; be surgically sterilised (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom if sexually active with a female partner of childbearing potential for at least 3 months after dosing.
• No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function), and ECG, as determined by the investigator. Male aged between 18 years and 55 years at screening, inclusive.

Exclusion Criteria

• History of severe digestive system disease or having a digestive disease currently within a month of screening or before first dosing, and may affect drug absorption or have safety risks.
• Severe infections, injuries or surgeries within 3 months of screening or before first dosing, or plan to undergo any surgeries during the trial.
• Use of any medicine affecting liver metabolism within 1 month of screening (see Appendix 1); use of any prescription medications within 14 days or 5 half-lives prior to dosing, use of any over-the-counter medicine or herbal products within 7 days prior to dosing; intention to use any other medicine during the trial.
• Whole blood donation or loss of more than 200 mL of blood within 1 month prior to dosing; or blood donation or loss of more than 400 mL of blood within 3 months prior to dosing; or plasma donation within 14 days prior to dosing; or received blood within 8 weeks prior to dosing.
• History of allergy to the study drug or any component of it.
• History of regular alcohol consumption in the past 1 month exceeding an average weekly intake of 21 standard drinks: 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor).
• Subject has used more than 5 tobacco or nicotine-containing products per day in the 6 months prior to dosing and is unable to refrain from use of such products from at least 48 hours prior to check-in through to the final study visit.
• Treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of dosing.
• History of drug abuse within 2 years prior to screening.
• Other conditions or laboratory abnormality that may increase the risk associated with study participation or IP administration or interfere with the interpretation of study results and, at the discretion of the investigator, makes the subject inappropriate for entry into this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Atridia Pty Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Na Li

Role: STUDY_DIRECTOR

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Locations

Linear Clinical Research

Nedlands, Western Australia, Australia

Countries

Australia

Other Identifiers

HRS4800-I-101-AUS

Identifier Type: -

Identifier Source: org_study_id